Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

Obesity pipeline

What is next, and who is running it?

Programs by company or class, across phase, filing, approval, and a stop.

Phase 1 on
ClassNone selected
MechanismNone selected

Phase 1 included.

Clear filters

94 of 94 programs on this matrix

Phase 1Phase 2Phase 3FiledApprovedDiscontinuedStage n/r
Abbott1 program
Sibutramine

Phase 3

once daily, oral

Monoamine reuptake · Abbott

AbbVie2 programs
Aconcagua Bio, Inc1 program
ACCG-2671

Phase 1/2

oral

Amylin · Aconcagua Bio, Inc

Alizyme1 program
Cetilistat

Phase 1

Dosing n/r

Class not reported · Alizyme

Altimmune1 program
Amgen1 program
Arrowhead1 program
Ascletis Pharma (China) Co1 program
ASC30

Phase 3

once daily, oral and injection

Class not reported · Ascletis Pharma (China) Co

AstraZeneca5 programs
Biohaven Therapeutics1 program
Taldefgrobep

Phase 2

once weekly, injection

Class not reported · Biohaven Therapeutics

Boehringer Ingelheim1 program
Survodutide

Registry, Dec 8, 2026

once weekly, subcutaneous

GLP-1/glucagon · Boehringer Ingelheim

BrightGene Bio-Medical Technology Co1 program
BGM0504

Registry, Feb 28, 2027

once weekly, oral and injection

GLP-1/GIP · BrightGene Bio-Medical Technology Co

Carmot Australia First Pty Ltd1 program
CT-996

Phase 1

oral

Class not reported · Carmot Australia First Pty Ltd

Carmot Therapeutics, Inc1 program
CT-868

Phase 2

once daily, injection

Class not reported · Carmot Therapeutics, Inc

Company n/r3 programs
Dulaglutide

Phase 3

once weekly, injection

GLP-1 RA · Company n/r

Loxenatide

Phase 2/3

injection

Class not reported · Company n/r

Beinaglutide

Stage n/r

once weekly, injection

GLP-1 RA · Company n/r

Corbus Pharmaceuticals1 program
CRB-913

Phase 1

Dosing n/r

Class not reported · Corbus Pharmaceuticals

CSPC Baike (Shandong) Biopharmaceutical Co1 program
TG103

Phase 3

once weekly, injection

GLP-1 RA · CSPC Baike (Shandong) Biopharmaceutical Co

Eli Lilly8 programs
Empros Pharma AB1 program
Orlistat

Approved

once monthly, oral

Lipase inhibitor · Empros Pharma AB

Fujian Shengdi Pharmaceutical Co1 program
Ribupatide

Registry, Oct 31, 2027

once weekly, oral and injection

GLP-1/GIP · Fujian Shengdi Pharmaceutical Co

Gan & Lee Pharmaceuticals1 program
Bofanglutide

Registry, Jun 30, 2027

every 4 weeks, injection

GLP-1 RA · Gan & Lee Pharmaceuticals

Gasherbrum Bio, Inc1 program
Aleniglipron

Phase 3

once daily, oral

Oral small molecule · Gasherbrum Bio, Inc

GSK1 program
Albiglutide

Phase 3

once weekly, oral and injection

Class not reported · GSK

Guangdong Raynovent Biotech Co1 program
RAY1225

Phase 3

once weekly, oral and injection

Class not reported · Guangdong Raynovent Biotech Co

Hangzhou Sciwind Biosciences Co1 program
Ecnoglutide

Registry, Jan 5, 2027

once weekly, oral and injection

GLP-1 RA · Hangzhou Sciwind Biosciences Co

Hanmi1 program
HM15211

Phase 1

injection

Class not reported · Hanmi

Hengrui1 program
Noiiglutide

Phase 3

once daily, oral and injection

Class not reported · Hengrui

Huadong Medicine3 programs
HDM1002

Phase 3

once daily, oral

GLP-1 RA · Huadong Medicine

HDM1702

Phase 3

once weekly, injection

Class not reported · Huadong Medicine

HDM1005

Registry, Dec 2026

once weekly, injection

GLP-1/GIP · Huadong Medicine

Innovent1 program
Mazdutide

Registry, Dec 31, 2026

once weekly, oral and injection

GLP-1 RA · Innovent

Inversago Pharma1 program
Monlunabant

Phase 2

once daily, oral

CB1 · Inversago Pharma

Merck1 program
MindRank AI Ltd1 program
MDR-001

Phase 3

oral

Small molecule · MindRank AI Ltd

NeuroBo Pharmaceuticals Inc1 program
DA-1726

Registry, Nov 9, 2026

injection

Class not reported · NeuroBo Pharmaceuticals Inc

NeuroSearch1 program
Tesofensine

Phase 2

daily

Monoamine reuptake · NeuroSearch

Novo Nordisk9 programs
Orexigen Therapeutics, Inc1 program
PegBio Co1 program
Visepegenatide

Phase 1/2

once weekly, injection

Class not reported · PegBio Co

Pfizer5 programs
Regeneron3 programs
Rhythm2 programs
LB54640

Phase 2

daily, oral

Class not reported · Rhythm

Setmelanotide

Registry, Mar 13, 2027

once daily, injection

MC4R · Rhythm

Roche3 programs
CT-388

Registry, Nov 12, 2027

once weekly, injection

GLP-1/GIP · Roche

Sanofi3 programs
Scholar Rock1 program
Scohia1 program
Shandong Suncadia Medicine Co1 program
Safiglipron

Phase 3

oral

Oral small molecule · Shandong Suncadia Medicine Co

Shanghai Yinnuo Pharmaceutical Technology Co1 program
Efsubaglutide Alfa

Registry, Nov 30, 2026

once weekly, injection

GLP-1 RA · Shanghai Yinnuo Pharmaceutical Technology Co

Shanghai Yinnuo Pharmaceutical Technology Co.1 program
Supaglutide

Phase 2/3

weekly, oral and injection

GLP-1 RA · Shanghai Yinnuo Pharmaceutical Technology Co.

Shionogi1 program
Velneperit

Phase 2

once daily, oral

Class not reported · Shionogi

Skye Bioscience1 program
Nimacimab

Registry, Nov 20, 2026

injection

Class not reported · Skye Bioscience

Terns, Inc1 program
TERN-601

Phase 2

once daily

Oral small molecule · Terns, Inc

The United Bio-Technology (Hengqin) Co1 program
UBT251

Registry, Jan 14, 2027

once weekly, oral and injection

GIP/GLP-1/glucagon · The United Bio-Technology (Hengqin) Co

Verdiva Bio Dev Limited1 program
VRB-101

Phase 2

weekly, oral

Class not reported · Verdiva Bio Dev Limited

Veru Inc1 program
Enobosarm

Phase 2

weekly, oral and injection

SARM · Veru Inc

Viking Therapeutics2 programs
Vincentage Pharma Co1 program
VCT220

Phase 3

once daily, oral

Oral small molecule · Vincentage Pharma Co

VIVUS1 program
Zafgen1 program
Beloranib

Phase 3

weekly, injection

MetAP2 inhibitor · Zafgen

Zealand Pharma1 program
Dapiglutide

Phase 2

once weekly, injection

GLP-1 RA · Zealand Pharma